Karolinska Development's Portfolio Company Anacardio Raises Sek 33 Million To Progress Clinical Development Of A Novel Therapy For Heart Failure
Karolinska Development's Portfolio Company Anacardio Raises Sek 33 Million To Progress Clinical Development Of A Novel Therapy For Heart Failure
02/03/22, 10:38 AM
Location
stockholmMoney raised
kr33 million
Round Type
seed
STOCKHOLM, SWEDEN February 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a fundraising of SEK 33 million comprised of a convertible loan. Karolinska Development participated in this important funding, which enables AnaCardio to proceed with the clinical development plans for the company’s lead asset AC01.
Company Info
Location
stockholm, stockholms län, sweden
Additional Info
With the new capital injection the company can complete the preparations to start a clinical phase 1b/2a-study with its lead asset AC01 in 2022. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. Karolinska Development participated in this important funding, which enables AnaCardio to proceed with the clinical development plans for the company’s lead asset AC01. AnaCardio is now well financed to complete the preparations of a clinical phase 1b/2a-study, expected to start in 2022,” says Viktor Drvota, CEO, Karolinska Development.